Open AccessEffects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure
Author(s) -
Inga Thráinsdóttir,
H. von Bibra,
Klas Malmberg,
Lars Rydén
Publication year - 2004
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-200407000-00014
Subject(s) - trimetazidine , medicine , heart failure , cardiology , ejection fraction , diabetes mellitus , type 2 diabetes , cardiac function curve , endocrinology
Congestive heart failure and type 2 diabetes have a deleterious prognosis when combined. Trimetazidine, a metabolic agent with anti-ischemic properties, reduces fatty acid beta-oxidation via decreased 3-ketoacyl-coenzyme-A thiolase activity thereby facilitating energy production via the glycolytic pathway.